|
|
|
Rozerem TV ad
|
Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN), versus binding to GABA-A receptors, such as with drugs like zolpidem, eszopiclone, and zaleplon. Ramelteon is approved by the FDA for long-term use.
Ramelteon does not show any appreciable binding to GABA-A receptors, which are associated with anxiolytic, myorelaxant, and amnesic effects.
|
|
| Rate this file (No vote yet) |
|
|
|
|
|
|
